Member Info for AgentB

There are certainly minks in China -farmed for their fur.

https://www.nationalgeographic.com/news/2016/08/wildlife-china-fur-farming-welfare/

Did you listen to the Q&A? I confess that I don’t understand your post, but I do remember a positive response to a question about glycosylation at the end of the session.

Rowka’s posts have two advantages over War and Peace. First, they are educational about our investment and secon, they do not inflict repetitive strain injury on the reader - which is what happened to me when reading the paperback version of W&P.

https://youtu.be/1JFXHs_Efe8

This guy is deemed to be (and can be) comedy genius but if I had had to sit through this sketch - one hour of the same endlessly repeated paragraph, I think I would have had to give him a ‘Wallsend Kiss‘. I have had many more laughs while reading this BB!

When I first joined this BB and share, I asked for the background story regarding the good ship Eurasia and all her crew. I’m very glad that I did. Being in on the joke has made this a hugely entertaining experience. Hoping that we are nearing a safe harbour, but I’ve stocked up on rum provisions just in case. And Captain Tilly, you really should write a book or comedy scripts or something. There’s potential for a great double act with JTMacs - or is that a threesome with the fragrant Septic Lil involved?

Excl China!

Encapsulates the argument for antigen testing over PCR and Antibody. Only PCR and antigen tests show current infectiousness. Both are effective in showing the presence of Covid 19 in the first two days before symptoms are seen and in the 7-10 days thereafter ( the most infectious period). The advantage of antigen testing over PCR is that it doesn’t display the long residual results whereby a patient who has recovered and is no longer infectious still tests positive.

As for antibody tests, they can’t be part of the Moonshot script - particularly if there is no clarity as to whether antibody immunity lasts or can deal with viral mutations

Well done again to Sir Al and his wonderful team.

Not only do they have significant skin in the game from their very astute share purchases when the price crashed, they also have a 150 million bonus scheme to incentivise them to grow the company by 2/3 by 2023

“Under the scheme, key top executives will share a maximum payout of £150m if Bohoo’s market value can be increased by 66% from £4.54bn as measured on 16 June to £7.55bn by 17 June 2023. At the lower end of the scheme, if the market capitalisation reaches £6.29bn at the end of the three years, the payout pot will be £50m. To achieve the maximum target, Boohoo’s sales will need to increase at an 18% average growth rate over the next three years.”

https://www.theguardian.com/business/2020/jun/26/boohoo-bosses-in-line-for-150m-bonus-as-part-of-incentive-plan

https://www.thisismoney.co.uk/money/markets/article-8464437/Boohoo-bosses-eye-150m-bonus-incentive-scheme.html

Agree. The full report will also be liked by ESG ratings agencies.

Almost word for word the same negative spin in the Telegraph

https://www.telegraph.co.uk/business/2020/09/25/boohoo-pledges-tackle-unacceptable-failures-supply-chain/
I guess we can expect a weekend of this - especially from the Sunday Times!

Looks like the press is determined to put negative spin on again. I just hope that BOO have got their counter PR ready.

https://www.spectator.co.uk/article/could-we-see-covid-anti-virals-before-a-vaccine-
Sorry, forgot link.

I saw the rumour about Vallance holding £600,000 worth of shares in GSK in the below the line comments of this Spectator article. No idea whether true or not.

Fantastic price to buy before ‘last orders’!

Agree @Paulcon. The crucial piece of missing information is how expensive/accessible the microchip readers that deliver the test results will be. Perhaps the Govt should order them for GP surgeries?

Sadly, I have to agree. This was not the time or place to give individual members of staff their 15 minutes of fame. A sleek and short demo with professional voiceover was what was needed.

GB was careful to give both affimers and Aptamer equal prominence

Is the global player

Equally, why bait the trolls? It just gives them a chance to spew more negativity.

Interesting detail from the RNS (observation taken from SKIN BB)

Microtox BT is expected to be a Class 1 medical device[ii].

Class I Medical Devices

Medical devices class I have the lowest perceived risk. The manufacturers of such devices can choose one out of three possible CE marking routes. In this regard, they should consider the following: if the medical device is sterile, e.g., a personal protection kit; if the medical device has measuring functions, e.g., stethoscope; and, if it’s not sterile, nor measuring, e.g., corrective glasses. If your product is class I, and it’s not a sterile or measuring device, then all you need to do is to self-certificate it, and formally declare its compliance with the applicable requirements of the MDD via a written statement. If it’s a sterile or a measuring medical device, then you will need a Notified body assessment.

[ii] https://support.ce-check.eu/hc/en-us/articles/360008712879-Classification-Of-Medical-Devices-And-Their-Routes-To-CE-Marking.